Swamy Yeleswaram, CDO
Professional Overview
Swamy Yeleswaram is a seasoned pharmaceutical executive with over 30 years of experience driving innovation and operational excellence. As the Chief Development Officer (CDO) at Rapport Therapeutics, he is responsible for leading the company's drug development strategy, overseeing clinical trial operations, and guiding the successful advancement of the company's pipeline of novel therapeutics.
Experience Summary
Current Role
As the CDO at Rapport Therapeutics, Swamy is leveraging his deep expertise in drug development to accelerate the company's progress in bringing transformative treatments to patients. He is responsible for establishing and executing the clinical development plan, ensuring the timely and efficient completion of clinical trials, and collaborating with cross-functional teams to optimize the company's regulatory and commercial strategies.
Career Progression
Swamy's distinguished career in the pharmaceutical industry spans over three decades. Prior to joining Rapport Therapeutics, he served as the Entrepreneur in Residence at Third Rock Ventures, where he provided strategic guidance and operational support to the firm's portfolio companies. Before that, he held the role of Group Vice President at Incyte, where he was instrumental in the successful development and commercialization of several of the company's key products. Swamy also held positions of increasing responsibility at DuPont Pharmaceuticals and Bristol-Myers Squibb, where he contributed to the advancement of multiple drug candidates through the clinical pipeline.
Academic Background
Swamy holds a Ph.D. in Organic Chemistry from the University of Delaware, where his research focused on the development of novel synthetic methodologies and their application in the synthesis of biologically active compounds. His academic background, combined with his extensive industry experience, has equipped him with a deep understanding of the complexities involved in drug discovery and development.
Areas of Expertise
Swamy's areas of expertise include:
- Clinical development strategy and execution
- Regulatory affairs and interactions with health authorities
- Project management and cross-functional collaboration
- Translational research and biomarker development
- Pharmaceutical operations and quality assurance
- Strategic planning and business development
Professional Impact
Throughout his career, Swamy has played a pivotal role in the successful advancement of numerous drug candidates, contributing to the development of therapies that have had a significant impact on patient care. His proven track record of driving innovation, his collaborative leadership style, and his commitment to delivering tangible results make him a valuable asset to the Rapport Therapeutics team as they work to address unmet medical needs in the pharmaceutical industry.
Conclusion
Swamy Yeleswaram is a seasoned pharmaceutical executive with a demonstrated history of driving drug development and operational excellence. As the CDO of Rapport Therapeutics, he is poised to leverage his extensive industry experience and technical expertise to guide the company's pipeline of novel therapeutics towards successful clinical development and commercialization, ultimately benefiting patients in need.
